secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0001367644-22-000051
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent appoints Harsanyi chairman, Katkin to board; El-Hibri retires as executive chairman
--------------------------------------------------------------------------------

- Zsolt Harsanyi, Ph.D., independent director since 2004, appointed non-executive chairman effective April 1, 2022.
- Keith Katkin appointed Class I independent director, receives initial equity award of $375,000 in RSUs vesting over 3 years.
- Founder Fuad El-Hibri retires as executive chairman; enters consulting agreement at $20,000/month (up to 20 hours) through March 2024.
- Board eliminates executive chairman role; Marvin White, Jerome Hauer, Kathryn Zoon appointed chairs of audit, strategic operations, and scientific review committees.
- El-Hibri's unvested equity awards continue to vest during consulting term; subject to non-compete and non-solicitation through 12 months post-termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764422000051/0001367644-22-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764422000051/ebs-20220317.htm
  HTML page:      https://secwatch.observer/filing/0001367644-22-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer